Huntingdon Life Sciences Acquires Harlan Laboratories
This acquisition creates a leading global organization offering full service, non-clinical, contract research and research models and services. The increased scale of the combined venture, approaching half a billion dollars in annual revenue, provides a strong platform for future growth and investment.
Brian Cass, CEO of Huntingdon Life Sciences, commented, “We are excited by the acquisition of Harlan, a highly respected leader in their market sectors. This acquisition is precisely in line with our strategy to broaden our support for the pharmaceutical, crop protection and chemical industries, as well as universities, government, and other research organizations. Our two companies have a long heritage and together we will maintain and build on our reputation for high quality science and innovation.”
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.